These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10202133)

  • 1. CA 125: fundamental and clinical aspects.
    Verheijen RH; von Mensdorff-Pouilly S; van Kamp GJ; Kenemans P
    Semin Cancer Biol; 1999 Apr; 9(2):117-24. PubMed ID: 10202133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)].
    Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D
    Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transient human anti-mouse antibodies (HAMA) interference in CA 125 measurements during monitoring of ovarian cancer patients treated with murine monoclonal antibody.
    Oei AL; Sweep FC; Massuger LF; Olthaar AJ; Thomas CM
    Gynecol Oncol; 2008 May; 109(2):199-202. PubMed ID: 18304620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.
    Skates SJ; Menon U; MacDonald N; Rosenthal AN; Oram DH; Knapp RC; Jacobs IJ
    J Clin Oncol; 2003 May; 21(10 Suppl):206s-210s. PubMed ID: 12743136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer tumor marker behavior in asymptomatic healthy women: implications for screening.
    Crump C; McIntosh MW; Urban N; Anderson G; Karlan BY
    Cancer Epidemiol Biomarkers Prev; 2000 Oct; 9(10):1107-11. PubMed ID: 11045795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical picture of women with early stage ovarian cancer.
    Eltabbakh GH; Yadav PR; Morgan A
    Gynecol Oncol; 1999 Dec; 75(3):476-9. PubMed ID: 10600311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
    Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
    J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
    Markman M; Federico M; Liu PY; Hannigan E; Alberts D
    Gynecol Oncol; 2006 Oct; 103(1):195-8. PubMed ID: 16595148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
    Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [CA-125 antigen].
    Zakrzewska I
    Postepy Hig Med Dosw; 2002; 56(1):29-38. PubMed ID: 11987487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospectively detected cancer in familial breast/ovarian cancer screening.
    Dørum A; Heimdal K; Løvslett K; Kristensen G; Hansen LJ; Sandvei R; Schiefloe A; Hagen B; Himmelmann A; Jerve F; Shetelig K; Fjaerestad I; Tropé C; Møller P
    Acta Obstet Gynecol Scand; 1999 Nov; 78(10):906-11. PubMed ID: 10577622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One biologic marker (carbohydrate antigen-CA 125), two different diseases (ovarian cancer and congestive heart failure): practical implications of monitoring CA 125 serum levels. A case report.
    Faggiano P; D'Aloia A; Bignotti T; Dei Cas L
    Ital Heart J; 2003 Jul; 4(7):497-9. PubMed ID: 14558304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumour markers in ovarian tumours.
    von Schlippe M; Rustin GJ
    Forum (Genova); 2000; 10(4):383-92. PubMed ID: 11535987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ovarian cancers and CA 125 in 2006].
    Lambaudie E; Collinet P; Vinatier D
    Gynecol Obstet Fertil; 2006 Mar; 34(3):254-7. PubMed ID: 16529967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibins and ovarian cancer.
    Robertson DM; Pruysers E; Burger HG; Jobling T; McNeilage J; Healy D
    Mol Cell Endocrinol; 2004 Oct; 225(1-2):65-71. PubMed ID: 15451569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biomarker in gynecologic malignancies].
    Isonishi S
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1003-7. PubMed ID: 15272576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique.
    Ren J; Chen Z; Juan SJ; Yong XY; Pan BR; Fan DM
    Cancer; 2000 Jan; 88(2):280-5. PubMed ID: 10640958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.